LOXL2 and familial pancreatic carcinoma: Stromal profiling in pancreatic cancer datasets identifies LOXL2-rich niches as protective barriers in primary tumors, whereas LOXL2 depletion in liver metastases correlates with accelerated progression, warranting reassessment of anti-stromal therapies targeting collagen remodeling (Jiang et al., 2020).